Investigation of the long-term sustainability of changes in appetite after weight loss by Nymo, S. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Investigation of the long-term sustainability of changes in appetite after weight loss
Nymo, S.; Coutinho, Sr; Eknes, Ph; Vestbostad, I.; Rehfeld, Jf; Truby, H.; Kulseng, B.;
Martins, C.
Published in:
International Journal of Obesity
DOI:
10.1038/s41366-018-0119-9
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Nymo, S., Coutinho, S., Eknes, P., Vestbostad, I., Rehfeld, J., Truby, H., ... Martins, C. (2018). Investigation of
the long-term sustainability of changes in appetite after weight loss. International Journal of Obesity, 42(8),
1489-1499. https://doi.org/10.1038/s41366-018-0119-9
Download date: 03. Feb. 2020
International Journal of Obesity (2018) 42:1489–1499
https://doi.org/10.1038/s41366-018-0119-9
ARTICLE
Clinical research
Investigation of the long-term sustainability of changes in appetite
after weight loss
S Nymo1,2 ● SR Coutinho1 ● PH Eknes1 ● I Vestbostad1 ● JF Rehfeld3 ● H Truby4 ● B Kulseng1,2 ● C Martins1,2
Received: 23 August 2017 / Revised: 23 April 2018 / Accepted: 30 April 2018 / Published online: 21 June 2018
© The Author(s) 2018. This article is published with open access
Abstract
Background/Objective Diet-induced weight loss (WL) leads to a compensatory increase in appetite and changes in the
plasma concentration of appetite-regulating hormones are likely to play a role. Whether these changes are transient or
sustained remains unclear. This study aimed to assess if changes in subjective and objective appetite markers observed with
WL are sustained after 1 year (1Y).
Subjects/Methods In total 100 (45 males) individuals with obesity (BMI: 37 ± 4 kg/m2, age: 43 ± 10 years) underwent
8 weeks (wks) of a very-low energy diet (VLED), followed by 4 wks refeeding, and a 1Y maintenance program. Fasting/
postprandial subjective ratings of hunger, fullness, desire to eat, and prospective food consumption (PFC) were assessed, and
plasma concentration of active ghrelin (AG), total peptide YY (PYY), active glucagon-like peptide 1, cholecystokinin
(CCK), and insulin measured, at baseline, week 13 (Wk13) and 1Y.
Results At Wk13, 16% WL (−18 ± 1 kg, P < 0.001) was associated with a signiﬁcant increase in fasting and postprandial
hunger ratings (P < 0.01 and P < 0.05, respectively), and postprandial fullness (P < 0.01) combined with a reduction in PFC
(P < 0.001). These were accompanied by a signiﬁcant rise in basal and postprandial AG concentrations (P < 0.001, for both),
a reduction in postprandial CCK (P < 0.01) and in basal and postprandial insulin (P < 0.001). At 1Y follow-up, with
sustained WL (15%; −16 ± 1 kg, P < 0.001), fasting hunger and postprandial fullness ratings remained increased (P < 0.05
for both), and postprandial PFC reduced (P < 0.001). Basal and postprandial AG remained elevated and insulin reduced (P <
0.001, for all), while postprandial CCK was increased (P < 0.01) and PYY decreased (P < 0.001).
Conclusion With a 15% sustained WL at 1Y, the drive to eat in the fasting state is increased, but this may be balanced out by
raised postprandial feelings of fullness. To assist with WL maintenance, new strategies are required to manage increased
hunger and drive to eat.
Introduction
Worldwide >40% of all adults have attempted to control
their body weight by weight loss strategies [1]. Weight loss
(WL) maintenance is now the most challenging part within
obesity management as relapse is common and only
10–20% succeed in maintaining their lower body weight
long-term [2, 3]. Reasons for recidivism are poorly under-
stood and likely to be complex, involving a combination of
reduced motivation and compliance to restrict energy intake
by dieting and increase energy expenditure via exercise
regimens [4–7], together with metabolic, neuroendocrine
and autonomic adaptive responses that oppose the reduced
obese state [8–11].
The landmark papers by Leibel et al. [10] and Dulloo
et al. [11] showed that WL is followed by a reduction in
total energy expenditure (TEE) larger than predicted and,
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despite that, an increase in hunger and hyperphagia. Since
then, reviews by Cornier et al. [8], Rosenbaum et al. [9] and
Doucet et al. [12], among others, have described the com-
pensatory mechanisms activated with WL, on both sides of
the energy balance equation, which may contribute to
weight re-gain.
A recent study has estimated that the increased appetite
seen with WL is probably threefold larger than the corre-
sponding reduction in TEE and likely the main driver of
weight re-gain [13]. Several studies, that use visual analo-
gue scales (VAS) to measure appetite, demonstrate that diet-
induced WL, outside of ketosis, is associated with increased
hunger feelings in the fasted state [14–16], likely mediated
via an increase in plasma ghrelin concentration [15–17],
even though some studies report no change [18, 19]. The
impact of WL on fullness feelings [15, 16, 20] and secretion
of peptides signalling satiety is, unfortunately, less clear
[15, 16, 20, 21].
Whether the changes in appetite associated with WL are
sustained in the long-term remains a point of debate, as the
available research is inconsistent in its ﬁndings [15, 20, 21],
with different methods to measure appetite being employed
and different hormonal fractions being measured. Sumithran
et al. [15] reported a sustained increase in subjects feelings
of hunger using VAS, plus an increase in ghrelin plasma
concentration at 1 year follow-up, as well as no change in
postprandial concentration of active glucagon-like peptide 1
(GLP-1) and a reduction in total peptide YY (PYY), after an
initial 12% WL followed by 50% regain. However, another
study reported a sustained increase in both total GLP-1 and
PYY3–36 postprandial secretion after a 12% sustained WL at
1 year follow-up [21], while another showed no change in
active GLP-1 postprandial secretion after 6 months of sus-
tained WL maintenance [20]. Moreover, from our knowl-
edge, no study has determined if sex modulates the changes
in appetite seen with WL. This is of great importance given
that sex has been shown to modulate appetite sensations and
the secretion of several appetite-related hormones [22, 23].
The primary aim of this study was to determine if changes
in appetite (both subjective feelings of appetite using VAS
and objective plasma concentrations of appetite-related
hormones) seen after WL, are sustained at 1-year (1Y)
follow-up. A secondary aim was to determine if sex mod-
ulates any changes in appetite.
Methods
Participants
Healthy adults with obesity (30 < BMI <50 kg/m2) from the
local community of Trondheim, Norway, were recruited for
this study by social media and articles in the local
newspaper. The study was approved by the regional ethics
committee (Ref., 2012/1901), registered in ClinicalTrial.
gov (NCT01834859) and conducted according to the
Declaration of Helsinki. All participants signed informed
consent before participation.
Participants had to be weight stable (<2 kg change over
the last 3 months), not dieting to lose weight and with a
sedentary lifestyle. Exclusion criteria were pregnancy,
breast-feeding, clinical signiﬁcant illness, including dia-
betes, previous WL surgery and/medication known to affect
appetite/metabolism or induce WL.
Study design
This was a longitudinal intervention study with repeated
measurements. Participants underwent an 8-week super-
vised very-low energy diet (VLED), followed by a 4-week
refeeding phase, and a 1-year weight maintenance program
(study diagram, Supplementary Figure I).
Weight loss phase
Participants followed for 8 weeks a VLED (Allévo, Karo
Pharma AS, Sweden) with 550/660 kcal/day, for females
and males respectively (carbohydrate 42%, protein 36%, fat
18% and ﬁbre 4%), plus no-energy ﬂuids and low starch
vegetables (max 100 g/day) [16].
At week 9, participants were gradually reintroduced to
normal foods, while withdrawing from the VLED products.
An individual diet plan (estimated energy requirements
(Ereq) at Wk9: 1690 ± 407 kcal/day) was prescribed by a
trained dietician tailored to individual energy requirements
(measured resting metabolic rate (RMR; Wk9 (1339 ± 252
kcal/day) × (physical activity level (PAL)) (extracted from
individual physical activity monitors (BodyMedia®, Sen-
seWear, Pittsburgh, USA), with 15–20% protein, 20–30%
fat, and 50–60% carbohydrate, aimed at weight stabilisation
[24]. VLED products ceased at the end of week 10.
Participants were asked not to change their PA levels
during this phase of the study. To check for compliance,
participants wore SenseWear armbands for 7-days at base-
line and at weeks 9 and 13 (Wk9 and Wk13). Data were
considered valid if the participants wore the device for
≥4 days, including at least 1 weekend day and >95% of the
time [25].
Weight maintenance phase
A 1Y follow-up program aimed at WL maintenance was
offered from Wk13. The diet plan provided at week 9 was
revised at week 13 by a trained dietician having into
account individual energy requirements (measured RMR
(1584 ± 285 kcal/day) × PAL at Wk13) and designed for
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weight maintenance (Ereq at Wk13: 2088 ± 520 kcal/day).
The multidisciplinary follow-up program included regular
individual and group based sessions, focusing on nutritional
counselling, increased PA levels and cognitive behavioural
therapy. A dietitian was present in all group meetings and
participants had an individual consultation with a dietitian
(1 h) every other month. Participants were also asked to
wear SenseWear armbands at 6 and at 12 months to record
PA levels.
Data collection
The following measurements were conducted at baseline,
Wk13 and 1Y follow-up.
Body weight and composition
Air-displacement plethysmography (BodPod, COSMED,
Italy) was used, while participants were in the fasting state.
Appetite measurements
Subjective appetite feelings (hunger, fullness, desire to eat
(DTE) and prospective food consumption (PFC)) were
measured with a 10-cm visual analogue scale (VAS) [26],
and blood samples for the analysis of appetite-related hor-
mones (active ghrelin (AG), active glucagon-like peptide 1
(GLP-1), total peptide YY (PYY), cholecystokinin (CCK),
and insulin) collected in fasting and every 30 min after a
standardised breakfast (600 kcal: 17% protein, 35% fat, and
48% carbohydrate) for 2.5 h. The breakfast consisted of 75
oat-bread (whole grain), 5 g butter, 40 g strawberry jam, 35
g cheese (38 E% fat) and 250 ml low fat (1.2 E% fat) milk.
The satiety quotient (SQ) for each appetite sensation, as
well as an average estimate, was calculated at each
assessment time point [27].
Plasma samples were analysed for AG, active GLP-1,
total PYY, CCK and insulin using a Human Metabolic
Hormone Magnetic Bead Panel (LINCOplex Kit, Millipore)
and CCK using an” in-house” RIA method [28] (intra-and
inter-assay CV were for AG, active GLP-1 and PYY <10%
and <20%; insulin <10% and <15% and CCK <5% and
<15%, respectively. Blood was collected into EDTA-coated
tubes. Around 1 ml of full blood was then transferred into a
micro tube and 20 μl mixture of inhibitors (10 μl of Pefabloc
(Roche Diagnostic, Germany) +10 μl DPP-IV (Merck
Millipore, Germany)) added. For CCK analysis, aprotinin
(DSM, Coatech AB, Kaiseraugst, Switzerland) (500 KIU/ml
whole blood) was added to the EDTA tube. Samples were
then centrifuged at 3200 rpm for 10 min at 18 °C and the
plasma frozen at −80 °C until further analysis. Samples
were analysed when all time points were available within
the same participant (average 1 year). The analysis was
performed by the same technician, except for CCK which
was analysed at Prof. Rehfelds lab (Rigshospitalet, Uni-
versity of Copenhagen, Copenhagen, Denmark).
Statistical analysis
Statistical analysis was performed with SPSS version 22
(SPSS Inc., Chicago, IL), and data presented as mean ±
SEM, except for baseline anthropometric data at baseline,
where mean ± SD was used. Statistical signiﬁcance was set
at P < 0.05. Data were analysed using linear mixed-effects
models, with restricted maximum-likelihood estimation,
including ﬁxed effects for time and sex, and their interac-
tion. Bonferroni correction was used for post hoc pairwise
comparisons. Average values for appetite ratings and
plasma concentrations of appetite-related hormones refer to
the average of all time points (fasting and postprandial).
Participants with data at 1Y were considered completers and
kept in the analysis. All the analysis was done for com-
pleters, except for changes in body weight where an
intention to treat analysis with baseline values carried for-
ward was used. The Benjamini–Hochberg method, which
controls for the false discovery rate [29] was used to adjust
for the large number of outcome variables. The association
between changes in subjective and objective appetite mar-
kers (both at Wk13 and 1Y), between the magnitude of WL
(both at Wk13 and 1Y) and the respective changes in both
subjective and objective appetite markers and between
changes in appetite at Wk13 and WL maintenance at 1Y
were investigated with Pearson or Spearmen correlation.
Results
Participants
In total 100 (55 females) participants fulﬁlled the study
entry criteria and started the study. Of those, 95 participants
completed the 8-week VLED (2 did not tolerate the VLED,
1 was excluded due to consumption of extra foods, 1
withdrew for personal reasons and 1 was lost to follow-up),
94 completed Wk 13 measurements (1 withdrew due to
family illness) and 71 (41 females) completed the full 1Y (8
withdrew due to own or family related illness, 3 due to work
constraints making it difﬁcult to return for measurements, 2
were excluded due to non-compliance as they had started a
new VLED, and 10 were lost to follow-up).
Baseline characteristics of the participants who started
and completed the study are presented in Table 1. There
were no signiﬁcant differences in any baseline measurement
between those who completed and those who did not
complete the study. Moreover, no differences were seen
between completers and non-completers regarding changes
Investigation of the long-term sustainability of changes in appetite after weight loss 1491
in appetite with WL (Wk13), even though completers lost
more weight at Wk13 (20.0 ± 5.0 vs 16.8 ± 4.4 kg, P <
0.05). Females were older (P < 0.05), lighter (P < 0.001)
and had a higher FM (%) than males (P < 0.001), but there
was no difference in BMI between sexes.
No changes in total PA duration or time spent in light,
moderate or vigorous activities were measured during the
WL phase. Time spent in vigorous activities was sig-
niﬁcantly increased at 6 months in all participants and
females (P < 0.01 and P < 0.05, respectively), but returned
to baseline levels at 1Y for all groups. Steps/day were
signiﬁcantly increased at 6 months in all participants (P <
0.01) and at 1Y in males only (P < 0.05). See Supplemen-
tary Table 1.
Body weight and composition
Changes in body weight are reported in Fig. 1. Mean WL at
Wk13 was 16% (−18 ± 1 kg), and this was maintained at
1Y follow-up in completers: 15% WL (−16 ± 1 kg, P <
0.001). The intention to treat analysis revealed an increase
in body weight from Wk13 to 1Y in all participants (6 ± 1
kg, P < 0.001), but body weight at 1Y was still signiﬁcant
lower than baseline (-11 ± 1 kg, P < 0.001).
FM (%) was signiﬁcantly decreased at Wk13 in all par-
ticipants, males and females (−9 ± 1%, −11 ± 1% and −7
± 1%, respectively, P < 0.001 for all groups) and remained
lower than baseline at 1Y (−9 ± 1%, −9 ± 1% and −8 ±
1%, respectively, P < 0.001 for all groups). The changes in
absolute FM over time were not statistical signiﬁcant dif-
ferent between sexes.
Appetite feelings
Hunger ratings in fasting were increased at Wk13 in all
participants (38%) and females (P < 0.01 and P < 0.05,
respectively), and this was sustained at 1Y follow-up in all
participants (22%) (P < 0.05). No signiﬁcant change over-
time were found for rating of fullness, DTE or PFC in
fasting (see Fig. 2). Females had overall signiﬁcant lower
ratings of PFC in fasting than males (5.4 ± 0.2 vs.6.1 ± 0.2
cm, P < 0.05).
Mean ratings of hunger were signiﬁcantly increased in all
participants and males at Wk13 (P < 0.01 and P < 0.05,
respectively) compared to baseline, but this was not sus-
tained at 1Y follow-up. Mean fullness ratings were sig-
niﬁcantly increased in all participants (10%) and males at
Wk13 (P < 0.01 and P < 0.05, respectively), and this was
sustained at 1Y follow-up in all participants (6%) (P <
0.01), but not in males. Females, had a signiﬁcant increase
in mean rating of fullness at 1Y follow-up only (P < 0.05).
Mean ratings of PFC were signiﬁcantly reduced in all par-
ticipants and males at Wk13 (P < 0.001 and P < 0.001,
respectively) and this was sustained at 1Y follow-up (P <
0.001, for both) (see Fig. 3). Females experienced a sig-
niﬁcant reduction in ratings of PFC at 1Y only (P < 0.05),
and had signiﬁcant lower overall rating of DTE (2.3 ± 0.2
vs. 3.3 ± 0.3 cm, P < 0.05) and PFC (3.4 ± 0.3 vs. 4.6 ± 0.3
cm, P < 0.01), compared to males. See Supplementary
Table 2A.
Table 1 Baseline characteristics of the participants
All (N=100) Completers (N=71)
All (N=100) Males (n=45) Females (n=55) All (N=71) Males (n=30) Females (n=41) P-value
Age (year) 42.5 ± 9.7 39.7 ± 9.1 44.8 ± 9.7** 43.4 ± 9.4 40.3 ± 9.2 45.6 ± 9.0* 0.140
Weight (kg) 110.3 ± 18.4 120.1 ± 19.6*** 102.3 ± 12.8 109.1 ± 18.7 120.4 ± 19.7*** 100.9 ± 12.9 0.313
BMI (kg/m) 36.7 ± 4.2 36.6 ± 4.9 36.7 ± 3.5 36.4 ± 4.0 36.6 ± 4.7 36.2 ± 3.5 0.274
FM % 44.1 ± 6.4 39.3 ± 5.7 47.9 ± 3.9*** 44.0 ± 6.4 39.2 ± 6.2 47.3 ± 4.0*** 0.849
Values are mean ± SD
BMI Body-mass index (calculated as the weight in kg divided by the square of the height in metres). FM Fat mass
P-values are for comparisons between all participants and completers. Symbols denote signiﬁcant differences between sexes in each group
*P < 0.05, **P < 0.01 and ***P < 0.001
Fig. 1 Body weight in all participants (intention to treat analysis) and
completers over time. Results presented as mean ± SEM
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Fig. 2 Subjective feelings of hunger (a), fullness (b), desire to eat (c),
and prospective food consumption (PFC) (d) in fasting, over time, in
all participants, males and females. Results presented as estimated
marginal means ± SEM. Symbols denote signiﬁcant differences from
baseline in all participants: **P < 0.01 and *P < 0.05, and females: ¥P <
0.05
Fig. 3 Mean fasting and postprandial ratings of hunger (a), fullness
(b), desire to eat (c), and prospective food consumption (PFC) (d) in
all participants over time. Results presented as estimated marginal
means ± SEM
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A signiﬁcant increase in SQ hunger was seen at Wk13
and this was sustained at 1Y in all participants (P < 0.01 and
P < 0.05, respectively) and females (P < 0.05, for both). See
Supplementary Table 3.
Appetite-related hormones
Basal concentration of AG was signiﬁcantly increased in all
participants, males and females at Wk13 (P < 0.001, P <
0.001, and P < 0.01, respectively) and this was sustained at
1Y follow-up (P < 0.001, P < 0.01, and P < 0.001, respec-
tively). Basal insulin concentration was signiﬁcantly
reduced in all participants, males and females at Wk13 (P <
0.01, P < 0.001, and P < 0.01, respectively) and this was
sustained at 1Y (P < 0.001, for all groups). Females had
signiﬁcant overall lower basal concentration of insulin (485
± 66 vs. 803 ± 69 pg/mL, P < 0.01) than males (see Fig. 4).
Mean AG plasma concentration was signiﬁcantly
increased at Wk13 in all participants, males and females (P
< 0.001, for all groups) and this was sustained at 1Y follow-
up (P < 0.001, for all groups). Mean total PYY concentra-
tion did not change signiﬁcantly by Wk13, but was sig-
niﬁcantly lower than baseline at 1Y follow-up in all
participants, males and females (P < 0.001, P < 0.001, and
P < 0.01, respectively). There was a signiﬁcant reduction in
mean CCK concentrations in all participants at Wk13 (P <
0.01), but an increase at 1Y follow-up, compared with
baseline, in all participants and males (P < 0.01, for both).
There was a signiﬁcant reduction in mean insulin con-
centration in all participants, males and females at Wk13 (P
< 0.001, for all groups), which was sustained at 1Y (P <
Fig. 4 Basal plasma concentrations of appetite-related hormones:
active ghrelin (AG) (a), active glukagon like peptide-1 (GLP-1) (b),
total peptide YY (total PYY) (c), cholecystokinin (CCK) (d) and
insulin (e), over time in all participants, males and females. Results
presented as estimated marginal means ± SEM. Symbols denote sig-
niﬁcant differences from baseline in all participants: ***P < 0.001,
males: ƗƗƗP < 0.001 and ƗƗP < 0.01 and females: ¥¥¥P < 0.001 and ¥¥P <
0.05
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0.001, for all groups) (see Fig. 5). See Supplementary
Table 2B.
Correlation analysis
No signiﬁcant correlation was found between changes in
subjective appetite feelings and changes in the plasma
concentrations of appetite-related hormones at any time
point (either at W13 or 1Y). The larger the WL at 1Y, the
larger was the increase seen in basal and postprandial
concentration of AG (r=−0.455 and r=−0.566, respec-
tively, P < 0.001, for both). The opposite was seen for
insulin, with a larger reduction in basal and postprandial
insulin plasma concentrations as the magnitude of WL
increased at 1Y (r= 0.282 and r= 0.277, respectively, P <
0.05 for both).
No signiﬁcant association was found between the chan-
ges in appetite (namely increased hunger and AG plasma
concentrations) seen with WL (Wk13) and WL main-
tenance/relapse at 1Y.
Discussion
In this longitudinal study, a 16% WL at Wk13 was sufﬁ-
cient to induce signiﬁcant health beneﬁts [30, 31], and was
associated with an increase in hunger, while postprandial
feelings of fullness and SQ hunger were increased and PFC
reduced. There was also a signiﬁcant increase in basal and
postprandial AG concentrations, a reduction in postprandial
CCK and in basal and postprandial insulin. At 1Y, and with
sustained WL (15%), fasting hunger, SQ hunger and
Fig. 5 Mean basal and postprandial plasma concentrations of appetite-
related hormones; a) active ghrelin (AG) (a), b) active glucagon-like
peptide-1 (active GLP-1) (b), c) total peptide YY (total PYY) (c), d)
cholecystokinin(CCK) (d), and e insulin (e), for all participants over
time. Results presented as estimated marginal means ± SEM
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postprandial fullness ratings were still increased and post-
prandial PFC reduced. Basal and postprandial AG remained
increased and insulin reduced, while postprandial CCK was
increased and PYY decreased at 1Y follow-up, compared to
baseline.
Few studies have been performed on the long-term sus-
tainability of changes in appetite with WL and, to date, the
results have been contradictory [15, 20, 21]. Sumithran
et al. (2011) [15], in a similar longitudinal study, reported a
sustained increase in postprandial hunger and DTE ratings,
and AG plasma concentrations and a reduction in the
postprandial concentration of total PYY and CCK at 1Y
follow-up [15]. However, the sample was composed of
predominately post-menopausal women (68%) and partici-
pants experienced an average 50% weight regain, after the
initial 14% WL. Iepsen et al. [21], using a similar study
design, reported an increase in the plasma concentration of
total ghrelin (both in the fasting and postprandial states), but
surprisingly, an increase in total GLP-1 and PYY3–36 post-
prandial concentrations with a sustained 13% WL at 1Y
follow-up. Unfortunately, they did not measure changes in
subjective feelings of appetite. Adam et al. [20], on the
other hand, reported an increase in the postprandial con-
centrations of active GLP-1 after an 8% WL, which was not
sustained after a 12-week WL maintenance period. The
present study is the largest evaluating the impact of sus-
tained WL maintenance, employing both subjective and
objective appetite markers, and offers a perspective of sex
being a mediator of outcome.
Even though ours and other studies tend to consistently
show a sustained increase in subjective feelings of hunger,
when using VAS, combined with an increase in ghrelin
(either active or total) with long-term WL [15, 21], changes
in postprandial fullness ratings and plasma concentrations
of satiety peptides remain controversial [15, 21]. Differ-
ences in the magnitude of WL and its sustainability, hor-
monal fractions measured and methods of analysis of gut
peptides [32–34] are likely to contribute to this inconsistent
picture alongside most studies having mixed gender.
Moreover, SQ hunger increased with WL, indicating a
larger reduction in hunger after the same test meal, which is
likely to reﬂect more accurate appetite sensation responses
[35].
The increase in postprandial fullness with WL and WL
maintenance is a novel. Sumithran et al. [15] reported no
change in fullness either with a 14% WL at Wk 10 or with a
7% WL maintenance at 1Y follow-up in 34 overweight and
obese individuals. Adam et al. [20] reported a similar out-
come after an 8% WL, both acutely and after 12 weeks of
WL maintenance in 32 overweight and obese individuals.
Inconsistencies may be due to differences in the magnitude
of WL, baseline participant characteristics and sample size.
In our study, an initial 16% WL was achieved, and this was
sustained at 1Y (15% WL) in 71 obese individuals, which is
a much larger WL and sample size compared with the other
available studies [15, 20]. In a study by Delgado-Aros et al.
[36], a higher BMI was associated with decreased post-
prandial fullness, which may explain why a so large WL,
and concomitant BMI reduction, in our study led to
increased fullness, when compared with baseline ratings.
Even though studies on the impact of BMI on gastric
capacity have not been consistent [37], a reduction in fast-
ing gastric capacity has been reported after ≥5% WL in
individuals with obesity [38]. It remains speculative if
changes in gastric capacity with WL contributed to
increased postprandial fullness in the present study.
Increased fullness after acute and sustained WL is unlikely
to be explained by changes in CCK secretion, given that a
reduction in CCK secretion was measured at Wk13, while
an increase was seen with sustained WL at 1Y follow-up.
Another explanation for the increased fullness with WL
may be an increased postprandial secretion GLP-1 and
PYY. Even though we saw no change in active GLP-1, and
a reduction in total PYY plasma concentrations, others have
shown that a large WL (14–15%) leads to an increase in the
secretion of both total GLP-1 [21, 39] and PYY3–36 [21].
Finally, it is possible that increased fullness reﬂects the
larger relative energy load of the test meal after WL.
To date, there is a dearth of information on the impact of
WL on CCK plasma concentrations. The available evidence
suggests that acute and rapid WL results in a reduction in
postprandial concentrations of CCK [15, 40], which is
consistent with our results, and probably reﬂects a lower
stimulation due to less food (and fat) intake. It remains
speculative why in the present study an increase in post-
prandial concentrations of CCK was seen with sustained
WL at 1Y follow-up, while in Sumithran’s study [15], with
a similar design (8 weeks of VLED followed by refeeding
and 1 year follow-up) and methodology (same RIA protocol
for CCK analysis), a reduction was reported. However, due
to continued dietetic support we achieved a 15% sustained
WL at 1Y follow-up, while Sumithran had a 50% weight
regain, with only a 7% WL at 1Y follow-up. This could
have had an impact on CCK concentrations, and the
increased postprandial CCK secretion may reﬂect a long-
term adaptation to substantial WL, but that requires further
substantiation.
The lack of association between subjective appetite
feelings and the plasma concentration of appetite-related
hormones seen in this study is not new [41, 42] and prob-
ably reﬂects the complexity of the appetite control system
and the fact that changes in appetite feelings are unlikely to
be attributable to alterations in a single hormone.
It has long been suggested that the increased hunger and
reduced satiety seen after WL are part of a compensatory
response that tries to bring body weight back to its set point
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[8, 43–45]. However, the ﬁndings from the present study:
increased fasting hunger and basal AG plasma concentra-
tions, as well as increased postprandial fullness, AG and
CCK in response to large sustained WL may suggest
otherwise. It is well known that obese individuals have
lower plasma concentration of ghrelin in fasting [46] and a
blunted postprandial secretion of total GLP-1 [39, 47],
active GLP-1 [48], total PYY [48, 49], and CCK [50] and
lower ghrelin postprandial suppression [46, 48]. Therefore,
our overall ﬁndings, with the exception of PYY, could
reﬂect a normalisation of appetite markers towards those
seen in healthy-weight individuals. This is supported by
Verdich et al. [39], who showed that postprandial total
GLP-1 concentration increased after a 19 kg WL toward
levels seen in a control normal-weight group. WL also leads
to a reduction in TEE proportional to the new reduced body
weight, even though some individuals may experience a
larger than predicted reduction—a mechanism known as
adaptive thermogenesis (AT) [10]. With, the exception of
AT, which seems to occur in only some individuals, the
changes in appetite and energy expenditure seen with WL
could, therefore, be seen as a normalisation towards a lower
body weight and not a compensatory mechanism that drives
relapse. This new hypothesis is supported by the fact that
neither us, nor Sumithran et al. [15] have reported any
association between the changes in appetite seen with WL
and long-term relapse at 1 year follow-up.
This study revealed several sex differences in the chan-
ges in appetite seen overtime with WL and WL main-
tenance. Hunger ratings in fasting were increased at Wk13
in females only, while mean postprandial ratings of hunger
and fullness were signiﬁcantly increased, and PFC reduced,
in males only at Wk13, and postprandial fullness was
increased in females only at 1Y follow-up. Moreover, mean
postprandial CCK plasma concentrations did not change at
any time point in females, while in males there was an
increase at 1Y follow-up, compared to baseline. The fact
that postprandial fullness was increased at 1Y follow-up in
females only may reﬂect the fact that in males there was a
tendency towards weight regain from Wk13 to 1Y, while
females continued to lose weight over time. More studies,
with larger sample sizes and equal sex distribution, are
needed to fully ascertain the potential modulating effect of
sex on the changes in appetite seen with WL and WL
maintenance and the explanatory mechanisms behind it.
This study has several strengths. First, it is the largest
longitudinal study to examine changes in appetite with
sustained WL. Second, it included both objective and sub-
jective markers of appetite. Third, the participants were able
to maintain their body weight at 1Y follow-up (compared
with Wk13), probably due to on-going and tailored advice
provided by dieticians. Finally, both males and females
were included in the study in similar numbers. There are
also some limitations. The multiplex assay used for the
measurements of appetite hormones (except for CCK) is
likely to result in less accurate and precise measurements
compared with optimised assays for each individual hor-
mone. The fact that the same type of test meal was given to
all participants, regardless of their Ereq, constitutes a lim-
itation. Females consumed a larger relative energy load
compared with males and the same test meal represented a
larger energy load with progressive WL. However, if we
had adjusted the test meal accordion to Ereq (smaller meals
in females compared with females and after WL) the
appetite response would be blunted, because the nutrient
stimuli would also be reduced, independently of the effect
of sex or WL on appetite. This study was not powered to
examine sex differences per se, so we are unable to draw
ﬁrm conclusions about sex differences in responses to WL.
Our ﬁndings have some important practical implications.
Patients with obesity who have lost and maintained sig-
niﬁcant amounts of weight via dieting, and beneﬁted in
terms of metabolic and overall health markers [30, 31],
should expect a sustained increase in hunger feelings in the
fasting state and to be prepared for these feelings to occur.
This increased drive to eat in fasting may impact on food
selection, eating rate and total energy intake, despite
increased postprandial fullness, and thus lead to positive
energy imbalance and increase the risk of weight regain.
Health professionals working with this patient group,
should be aware of the sustained increase in the drive to eat
in the fasting state and help individuals develop manage-
ment strategies to reduce the risk of overeating. However,
the changes in appetite seen with WL (increased hunger and
AG) were not associated with long-term relapse, which
likely reﬂects the complexity of body weight regulation
[51].
Conclusions
With a 15% sustained WL at 1Y follow-up, the drive to eat
in the fasted state is increased, which may, despite increased
postprandial fullness, drive overeating. Some sex differ-
ences were revealed, but larger studies are needed to sup-
port these ﬁndings. Future studies should evaluate if
changes in appetite markers with WL are part of a com-
pensatory response or a simple normalisation towards
healthy-weight values, its relationship with actual food
intake and its real impact on long-term WL maintenance.
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